SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.780
+0.080 (2.16%)
Mar 19, 2026, 4:00 PM EDT - Market closed

SAB Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
13.27-34.11-42.19-18.74-17.14
Depreciation & Amortization
3.084.793.753.291.65
Stock-Based Compensation
5.212.942.422.672.31
Other Adjustments
-62.66-5.628.58-10.453.48
Change in Receivables
-0.89-0.055.562.4512.56
Changes in Accounts Payable
1.480.92-2.7-0.78-2.94
Changes in Accrued Expenses
0.94-1.23-1.71-2.543.38
Changes in Other Operating Activities
-5.22-1.941.190.63-1.32
Operating Cash Flow
-44.78-34.29-25.12-23.461.99
Operating Cash Flow Growth
-----80.14%
Capital Expenditures
-0.93-0.34-0.2-2.17-10.94
Sale of Property, Plant & Equipment
0-0.040.08-
Purchases of Investments
-142.04-37.45---
Proceeds from Sale of Investments
21.2625.82---
Investing Cash Flow
-121.71-11.96-0.15-2.09-10.94
Long-Term Debt Issued
-0.520.771.242.84
Long-Term Debt Repaid
-0.28-1.29-1.03-2.26-1.09
Net Long-Term Debt Issued (Repaid)
-0.28-0.77-0.26-1.021.75
Issuance of Common Stock
168.730.020.017.7634.35
Repurchase of Common Stock
-0.01-0.02---
Net Common Stock Issued (Repurchased)
168.72-00.017.7634.35
Issuance of Preferred Stock
--67.15--
Net Preferred Stock Issued (Repurchased)
--67.15--
Other Financing Activities
-0.14-0.39-0.13-5.68-0.2
Financing Cash Flow
168.3-1.1766.771.0535.89
Effect of Exchange Rate Changes on Cash and Cash Equivalents
-0.21-0.240.02--
Net Cash Flow
1.6-47.6741.52-24.526.93
Free Cash Flow
-45.71-34.63-25.32-25.63-8.96
FCF Margin
--2618.65%-1130.71%-107.20%-14.71%
Free Cash Flow Per Share
-0.75-3.74-4.59-5.89-3.28
Levered Free Cash Flow
12.35-32.67-42.14-21.33-25.56
Unlevered Free Cash Flow
-49.6-40.7-37.76-30.44-23.56
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q